NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

BioNTech logo
$80.77 -0.61 (-0.75%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$81.50 +0.73 (+0.90%)
As of 11/20/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About BioNTech Stock (NASDAQ:BNTX)

Advanced

Key Stats

Today's Range
$80.27
▼
$82.87
50-Day Range
$80.77
▼
$100.87
52-Week Range
$79.52
▼
$124.00
Volume
1.71 million shs
Average Volume
997,830 shs
Market Capitalization
$20.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.44
Consensus Rating
Moderate Buy

Company Overview

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases.

The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio.

BioNTech works with partners to develop and distribute products internationally. It was co-founded by Ugur Sahin and Özlem Türeci; Sahin has served as the company’s chief executive officer.

AI Generated. May Contain Errors.

BioNTech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

BNTX MarketRank™: 
3.65063788027 of 5 stars

BioNTech scored higher than 73% of companies evaluated by MarketBeat, and ranked 157th out of 837 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 1 strong buy rating, 12 buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside Potential

    BioNTech has a consensus price target of $120.44, representing about 49.1% upside from its current price of $80.77.

  • Amount of Analyst Coverage

    BioNTech has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BioNTech's stock forecast and price target.
  • Earnings Growth

    Earnings for BioNTech are expected to grow in the coming year, from ($6.38) to ($5.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BioNTech is -11.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BioNTech is -11.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BioNTech has a P/B Ratio of 1.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.10% of the float of BioNTech has been sold short.
  • Short Interest Ratio / Days to Cover

    BioNTech has a short interest ratio ("days to cover") of 2.15, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BioNTech has recently decreased by 1.17%, indicating that investor sentiment is improving.
  • News Sentiment

    BioNTech has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for BioNTech this week, compared to 8 articles on an average week.
  • Search Interest

    Only 4 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added BioNTech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BioNTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,246,837.00 in company stock.

  • Percentage Held by Insiders

    19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    15.52% of the stock of BioNTech is held by institutions.

  • Read more about BioNTech's insider trading history.
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNTX Stock News Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
BioNTech (BNTX) Dropped, So What Is Driving Attention Now?
See More Headlines

BNTX Stock Analysis - Frequently Asked Questions

BioNTech's stock was trading at $95.20 on January 1st, 2026. Since then, BNTX stock has decreased by 15.2% and is now trading at $80.7730.

BioNTech SE Sponsored ADR (NASDAQ:BNTX) issued its quarterly earnings results on Tuesday, August, 4th. The company reported ($2.53) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by $0.14. The company's revenue was down 59.5% compared to the same quarter last year.
Read the conference call transcript
.

BioNTech's board initiated a share buyback plan on Thursday, May 7th 2026, which permits the company to repurchase $1 billion in outstanding shares, according to EventVestor. This means that the company could reacquire up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

The following companies are subsidiaries of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and more.

BioNTech (BNTX) raised $155 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 10,000,000 shares at $15.00-$16.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

BioNTech's top institutional shareholders include Dodge & Cox (1.46%), First Trust Advisors LP (0.39%), Assenagon Asset Management S.A. (0.30%) and GSK plc (0.26%). Insiders that own company stock include Sierk Poetting and Ugur Sahin.
View institutional ownership trends
.

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Advanced Micro Devices (AMD), Novavax (NVAX) and NIO (NIO).

Company Calendar

Last Earnings
8/04/2026
Today
11/22/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BNTX
CIK
1776985
Employees
7,807
Year Founded
2008

Price Target and Rating

High Price Target
$155.00
Low Price Target
$93.00
Potential Upside/Downside
+49.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.65
Research Coverage
20 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.29 billion
Net Margins
-61.39%
Pretax Margin
-60.67%
Return on Equity
-4.51%
Return on Assets
-3.96%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
8.55
Quick Ratio
8.52

Sales & Book Value

Annual Sales
$2.42 billion
Price / Sales
8.44
Cash Flow
$1.33 per share
Price / Cash Flow
60.64
Book Value
$80.61 per share
Price / Book
1.00

Miscellaneous

Outstanding Shares
252,884,000
Free Float
204,330,000
Market Cap
$20.43 billion
Optionable
Optionable
Beta
1.28

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:BNTX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners